fibrinopeptide-a and Colonic-Neoplasms

fibrinopeptide-a has been researched along with Colonic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for fibrinopeptide-a and Colonic-Neoplasms

ArticleYear
Pre- and postsurgery activation of blood coagulation in gastric and large bowel cancers: diagnostic, therapeutic and prognostic hints.
    Oncology, 1990, Volume: 47, Issue:3

    In 12 patients with gastric cancer and in 14 with large bowel neoplasia, classified according to the TNM system, some major blood indices of hemostasis, platelet activation and fibrinolysis were assessed before and for 1 month after surgery, to show whether possible variations of such indices may provide useful clues to follow-up, treatment effectiveness and prognosis. The following conclusions may be drawn: (1) the assay of platelets, fibrinogen, AT III, fibrin(ogen) degradation products, fragment X, platelet factor 4 has provided useful clues in neither group of patients; (2) preoperative high beta-thromboglobulin (beta-TG) is a reliable index of tumor presence in both gastric and large bowel cancer; (3) postoperative high beta-TG and fibrinopeptide A (FpA) are reliable indices of (a) tumor persistence in both gastric and large bowel cancer; (b) lymph node involvement in gastric much more than in large bowel cancer; (c) metastatic spreading from gastric cancer; (4) the FpA levels are proportional to the tumor mass in gastric cancer. The finding of lower plasma heparin levels in neoplastic patients, when compared with controls (20 patients having undergone abdominal surgery for extraneoplastic affections) suggests higher than conventional doses (5,000 units every 8 h s.c.) of the drug should be given to neoplastic patients in order to prevent thromboembolic bouts and possibly reduce metastatic spreading.

    Topics: Adult; Aged; Aged, 80 and over; beta-Thromboglobulin; Blood Coagulation; Colonic Neoplasms; Female; Fibrin Fibrinogen Degradation Products; Fibrinopeptide A; Heparin; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Stomach Neoplasms

1990
Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.
    Medical oncology and tumor pharmacotherapy, 1989, Volume: 6, Issue:2

    In 98 patients affected by colorectal cancer (43 patients with colon cancer, 55 patients with rectosigmoid cancer) the specificity of some tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) has been tested in evidencing the coexistence of liver metastases and the site of the primary tumor, i.e. the rectosigmoid region (rectum + 15 cm of the adjacent sigmoid colon) vs the rest of the colon. Liver metastases, present in 19 patients with colon cancer and in 24 with recto-sigmoid cancer, were previously ascertained by various instrumental investigations. Unlike previous studies which indicated CEA or alpha-FP as the most reliable markers to suggest the coexistence of liver metastases in such patients, the reported results allow the following sequence, in decreasing order of sensitivity, to be proposed: gamma-GT; FpA; CEA and GICA to a similar degree; TPA, which increases only when liver metastases from colon cancer are present; lastly, alpha-FP, which rises only in very few cases of massive hepatic involvement.

    Topics: alpha-Fetoproteins; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Colonic Neoplasms; Fibrinopeptide A; gamma-Glutamyltransferase; Humans; Liver Neoplasms; Peptides; Tissue Polypeptide Antigen

1989